Abstract
Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].
Current Diabetes Reviews
Title: Rubosixtaurin and other pkc Inhibitors in Diabetic Retinopathy and Macular Edema. Review
Volume: 5 Issue: 1
Author(s): M. Isabel Lopez Galvez
Affiliation:
Abstract: Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].
Export Options
About this article
Cite this article as:
Lopez Galvez Isabel M., Rubosixtaurin and other pkc Inhibitors in Diabetic Retinopathy and Macular Edema. Review, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314167
DOI https://dx.doi.org/10.2174/157339909787314167 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Basis of Ureterocele
Current Genomics Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Current Pharmaceutical Design Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Genetic and Genomic Approaches to Glomerulosclerosis
Current Molecular Medicine Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Chitosan and Its Use in Design of Insulin Delivery System
Recent Patents on Drug Delivery & Formulation Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006
Current Hypertension Reviews Antioxidant Effects of Glutathione and IGF in a Hyperglycaemic Cell Culture Model of Fibroblasts: Some Actions of Advanced Glycaemic end Products (AGE) and Nicotine
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Current Drug Targets Flavonoids as Promising Lead Compounds in Type 2 Diabetes Mellitus: Molecules of Interest and Structure-Activity Relationship
Current Medicinal Chemistry Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science